Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vaxart ( (VXRT) ) just unveiled an announcement.
On August 5, 2025, Vaxart received a stop work order for its Project Agreement under the Consortium Base Agreement with ATI, funded by BARDA. Despite this, the company can continue follow-up efforts for a Phase 2b study involving its oral COVID-19 vaccine candidate. On October 8, 2025, a follow-up notice clarified that BARDA intends to exclude the paused work from the Project Agreement, but Vaxart will still receive funding for evaluating the trial’s 5,000 participants. The company believes the trial data will provide valuable insights and support for advancing its COVID program.
The most recent analyst rating on (VXRT) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
Spark’s Take on VXRT Stock
According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral.
Vaxart’s overall score is primarily driven by its strong revenue growth but is significantly hampered by profitability issues and negative valuation metrics. Technical indicators suggest a bearish trend, and while the earnings call provided some positive developments, operational challenges and compliance issues weigh heavily on the stock’s outlook.
To see Spark’s full report on VXRT stock, click here.
More about Vaxart
Vaxart, Inc. operates in the biotechnology industry, focusing on developing oral vaccines, including a COVID-19 vaccine candidate. The company aims to innovate in the vaccine market with its oral pill format, which could offer an alternative to traditional injection-based vaccines.
Average Trading Volume: 735,908
Technical Sentiment Signal: Sell
Current Market Cap: $78.58M
See more insights into VXRT stock on TipRanks’ Stock Analysis page.